logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > Chemical Intermediates > Ethyl 7-chloro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate CAS 103877-51-6

Ethyl 7-chloro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate CAS 103877-51-6

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 103877-51-6

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15DAY

Payment Terms: L/C,D/A,D/P,T/T,Western Union,MoneyGram

Supply Ability: G,KG,TON

Get Best Price
Highlight:

4-oxo-1

,

4-dihydroquinoline-3-carboxylate CAS 103877-51-6

,

CAS 103877-51-6

Appearance::
Powder
CAS NO::
103877-51-6
Molecular Formula::
C16H16ClNO3
Molecular Weight::
305.76
EINECS NO::
600-496-4
MDL NO::
NA
Appearance::
Powder
CAS NO::
103877-51-6
Molecular Formula::
C16H16ClNO3
Molecular Weight::
305.76
EINECS NO::
600-496-4
MDL NO::
NA
Ethyl 7-chloro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate CAS 103877-51-6

Product Description:

Product Name: ethyl 7-chloro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate CAS NO: 103877-51-6


Synonyms:

7-Chloro-1-cyclopropyl-8-methyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid ethyl ester;7-chloro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate;3-Quinolinecarboxylic acid, 7-chloro-1-cyclopropyl-1,4-dihydro-8-methyl-4-oxo-, ethyl ester;


Chemical & Physical Properties:

Appearance: Powder

Assay :≥99.00%

Boiling Point: 448.7±45.0℃(Predicted)

Density   1.362±0.06 g/cm3(Predicted)

PKa: -3.24±0.40(Predicted)

Flash Point: 225.2±28.7℃

Vapor Pressure: 0.0±1.1 mmHg at 25℃

Index of Refraction: 1.621

Water Solubility: Insoluble (2.8E-3 g/L) (25℃)


Ozenoxacin is a novel non-fluoroquinolone antimicrobial for the treatment of pustular dermatitis and other skin infections by inhibiting DNA rotase and topoisomerase IV as a cream (10g, 1%) for the treatment of bacterial skin infections, including Gram-positive skin and soft tissue infections. The compound has been successfully completed in Phase III clinical trials for the treatment of adult Chemicalbook and children's pustular dermatitis, showing stronger antimicrobial activity, good safety and tolerability.


If you are interested in our products or have any questions, please feel free to contact us!


Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.